- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01646450
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
5. september 2015 opdateret af: Betta Pharmaceuticals Co., Ltd.
An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation
A single arm, open label, phase IV trial to evaluate safety and efficacy of icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR.
Studieoversigt
Detaljeret beskrivelse
A single arm, open label, prospective, phase IV trial to evaluate safety and efficacy of icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR.
- Primary endpoint to assess progression-free survival
- Secondary endpoints to assess the overall survival, objective response rate, disease control rate and so on.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
35
Fase
- Fase 4
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Shanghai
-
Shanghai, Shanghai, Kina, 200030
- Shanghai Chest Hospital Affliated to Shanghai Jiaotong Univercity
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
70 år til 80 år (Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB patients.
- Positive EGFR Mutation.
- No previous systemic anticancer therapy.
- Male and female patients aged over 70 years.
- Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site.
- Provision of written informed consent.
Exclusion Criteria:
- Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).
- Known severe hypersensitivity to icotinib or any of the excipients of this product.
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Icotinib
Icotinib: 125mg, oral administration, three times per day.
|
Icotinib: 125mg, oral administration, three times per day.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Progression free survival
Tidsramme: 12 months
|
PFS was defined as the time from the date of first dose of study medication to the date of first documentation of tumor progression or death due to any cause, whichever occurred first.
|
12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall survival
Tidsramme: 24 months
|
Overall Survival was assessed via calculation of the time to death due to any cause.
If a participant was known to have died, the time to death was defined as the time from the date of randomization to the date of death.
Otherwise, a participant was censored at the last date they were known to be alive.
|
24 months
|
Objective response rate
Tidsramme: 3-6 months
|
Number of participants with an objective response.
An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to RECIST, confirmed at least 28 days following the date of the initial response.
|
3-6 months
|
Number of Participants with Adverse Events as a Measure of Safety
Tidsramme: 18 months
|
Adverse events, Serious adverse events , incidence of and reason for study drug dose interruptions and discontinuations, laboratory assessments, vital signs.
|
18 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Han Baohui, MD, Shanghai Chest Hospital Affliated to Shanghai Jiaotong Univercity
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2012
Primær færdiggørelse (Forventet)
1. december 2015
Studieafslutning (Forventet)
1. april 2016
Datoer for studieregistrering
Først indsendt
17. juli 2012
Først indsendt, der opfyldte QC-kriterier
19. juli 2012
Først opslået (Skøn)
20. juli 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
9. september 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
5. september 2015
Sidst verificeret
1. september 2015
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- BD-IC-IV20
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Ikke-småcellet lungekræft
-
AHS Cancer Control AlbertaCross Cancer InstituteAfsluttetOmfattende Stage Small Cel Lung CancerCanada
-
Universitaire Ziekenhuizen KU LeuvenUkendtLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
Kliniske forsøg med Icotinib
-
Betta Pharmaceuticals Co., Ltd.RekrutteringIkke-småcellet lungekræft | Adjuverende terapi | EGFR følsom mutationKina
-
Sichuan Cancer Hospital and Research InstituteUkendt
-
Anhui Medical UniversityUkendt
-
Li PengBetta Pharmaceuticals Co., Ltd.AfsluttetNeurofibromatose type 2 | Vestibulær SchwannomaKina
-
Betta Pharmaceuticals Co., Ltd.UkendtIkke-småcellet lungekræftKina
-
Betta Pharmaceuticals Co., Ltd.Ukendt
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdAfsluttet
-
Cancer Institute and Hospital, Chinese Academy...UkendtIkke-småcellet lungekræftKina
-
Tianjin Medical University Cancer Institute and...Rekruttering
-
Betta Pharmaceuticals Co., Ltd.RekrutteringEGF-R positiv ikke-småcellet lungekræftKina